ArticleCancer biology & medicine2025

DB-1310, a HER3-targeting antibody-drug conjugate, has synergistic anti-tumor activity with trastuzumab in HER2- and HER3-expressing breast cancer.

Xi Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.